GLP-1 Medications and Skin Health: What the Research Shows

Introduction

GLP-1 receptor agonists — including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — have transformed metabolic medicine. But beyond blood sugar and body weight, these drugs are triggering a wave of dermatology research. From psoriasis clearance to the now-famous "Ozempic face," GLP-1 medications appear to reshape the skin in ways both promising and challenging.

A 2025 systematic review and meta-analysis in JAAD Reviews catalogued the full spectrum of cutaneous events associated with GLP-1 receptor agonists, finding both therapeutic potential in inflammatory skin disease and a distinct pattern of adverse aesthetic effects tied to rapid fat loss.

Evidence: "GLP-1 receptor agonists were associated with significant improvements in inflammatory skin conditions, while injection-site reactions and alopecia were the most frequently reported adverse cutaneous events." — JAAD Reviews, 2025. DOI: 10.1016/j.jadr.2025.00054

The picture that emerges is nuanced: GLP-1 medications can be both a skin ally and a skin stressor, depending on the condition, the patient, and the rate of weight loss.

How GLP-1 Medications Affect the Skin: The Mechanisms

GLP-1 receptors (GLP-1R) are not confined to the pancreas and gut. They are expressed on immune cells throughout the body — including macrophages, dendritic cells, and T lymphocytes — cells that also drive skin inflammation.

When GLP-1 receptor agonists bind to these immune cells, they suppress the nuclear factor kappa-B (NF-κB) pathway, a master regulator of inflammatory signaling. This reduces circulating levels of pro-inflammatory cytokines such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and interleukin-17 (IL-17) — the same cytokines that drive conditions like psoriasis and hidradenitis suppurativa (HS).

Beyond direct immunomodulation, metabolic improvements from these medications — including weight loss, improved insulin sensitivity, and lower advanced glycation end-products (AGEs) — create an anti-inflammatory systemic environment that can benefit skin at multiple levels.

Evidence: "GLP-1 receptor agonists mitigate psoriasis severity through systemic effects, including weight loss and improved glycemic control, and local immunomodulation via regulation of invariant natural killer T (iNKT) cells and AMPK activation in psoriatic plaques." — Haykal T, et al. Journal of Cosmetic Dermatology. 2025. DOI: 10.1111/jocd.16716

Therapeutic Benefits: Psoriasis and Hidradenitis Suppurativa

Psoriasis

Psoriasis is a chronic autoimmune skin disease affecting roughly 2–3% of the global population. Obesity is a well-established risk factor for more severe psoriasis, and weight-related inflammation amplifies disease activity. This creates a biologically plausible rationale for GLP-1 therapy.

In a 2025 open-label randomized clinical trial, 31 obese patients with psoriasis and type 2 diabetes received semaglutide for 12 weeks. The results were striking:

PASI score (Psoriasis Area and Severity Index) declined from a median of 21 to 10 (p = 0.002)
IL-6 levels dropped significantly (p < 0.05)
C-reactive protein decreased significantly (p < 0.05)
DLQI (Dermatology Life Quality Index) improved from a median of 14 to 4 (p = 0.002)

Evidence: "Semaglutide significantly reduced psoriasis severity in obese patients with T2DM, with PASI scores declining by more than 50% over 12 weeks alongside measurable reductions in systemic inflammation." — Biomolecules. 2025;15(1):46. DOI: 10.3390/biom15010046

These benefits appear to reflect a combination of weight-mediated effects and direct immunomodulation through GLP-1 receptor signaling on skin-resident immune cells.

Hidradenitis Suppurativa

Hidradenitis suppurativa is a chronic, painful inflammatory skin disease affecting hair follicles in the axillae, groin, and inframammary areas. It carries a heavy burden of morbidity and is closely linked to metabolic syndrome and obesity.

A 2025 retrospective multicenter study published in JAMA Dermatology examined 66 adults with HS treated with a GLP-1 receptor agonist for at least 3 months across 15 French dermatology centers. The most commonly prescribed agent was semaglutide (n = 48).

Key findings:

54% of patients achieved at least a 1-point reduction in HS-PGA (Physician's Global Assessment) score at 6 months
Reductions in flare frequency, pain scores, and abscess formation were observed
Adding semaglutide to ongoing biologic therapy lengthened flare-free intervals

Evidence: "Use of GLP-1 receptor agonists was associated with a reduction in disease severity, flares, and pain in patients with hidradenitis suppurativa — including those on concurrent biologic therapy." — Gouvrion L, et al. JAMA Dermatology. 2025. DOI: 10.1001/jamadermatol.2025.2723

A separate retrospective cohort study using TriNetX data confirmed that semaglutide use was associated with significantly lower HS-related healthcare utilization, including fewer emergency department visits and dermatology procedures.

Condition	Effect Size	Key Metric	Study Type
Psoriasis	PASI reduced by ~52%	21 → 10 at 12 weeks	RCT
Hidradenitis Suppurativa	54% achieved HS-PGA improvement	≥1-point reduction at 6 months	Retrospective multicenter
Systemic Inflammation	Significant IL-6 and CRP reduction	p < 0.05	RCT

The "Ozempic Face" Phenomenon

The same mechanism that drives weight loss — accelerated fat mobilization — can produce unintended aesthetic consequences, particularly in the face. "Ozempic face" has entered the cultural lexicon to describe a constellation of changes seen in patients who lose weight rapidly on GLP-1 therapy:

Facial volume loss — subcutaneous fat depletion in the cheeks, temples, and periorbital areas
Skin laxity and sagging — loss of structural support from fat pads
Accelerated apparent aging — hollowing and deepening of nasolabial folds
Muscle wasting contribution — loss of lean mass exacerbates tissue deflation

A 2024 review in Dermatological Reviews examined the cosmetic and dermatologic implications of this phenomenon, noting that the face is disproportionately affected because facial fat is lost faster than structural skin remodeling can compensate.

Evidence: "Semaglutide-induced rapid weight loss accelerates the appearance of facial aging through fat redistribution, collagen depletion, and reduced skin elasticity — presenting unique challenges for cosmetic dermatologists." — Montecinos A, et al. Dermatological Reviews. 2024. DOI: 10.1002/der2.70003

Importantly, this is not unique to semaglutide — any rapid weight loss can cause similar changes. The rate of loss matters more than the mechanism. Patients who lose weight slowly (0.5–1 kg/week) tend to have better skin retraction than those who lose rapidly (>1.5 kg/week).

Dermatologists are increasingly recommending:

Slower titration schedules to moderate weight loss rate
Resistance training to preserve lean mass and skin tension
Collagen-supportive nutrition (adequate protein, vitamin C)
Cosmetic interventions if clinically indicated (fillers, skin tightening procedures)

Cutaneous Side Effects to Watch For

Beyond aesthetic changes, GLP-1 receptor agonists carry a profile of skin-related adverse events that patients and clinicians should recognize:

Common (injection-site related):

Erythema (redness) at injection site
Pruritus (itching) at injection site
Localized rash or induration

Less common but reported:

Alopecia (hair loss) — one of the more frequently flagged adverse events in FDA FAERS data, typically telogen effluvium triggered by rapid caloric restriction and weight loss, not a direct drug effect
Urticaria and hypersensitivity reactions — rare but require discontinuation
Photosensitivity — anecdotal reports, particularly with tirzepatide

Evidence: "GLP-1 receptor agonists were associated with an increased risk of alopecia consistent with data from the FDA Adverse Event Reporting System; injection-site reactions including pruritus and erythema were the most common cutaneous adverse events across trials." — A Review of Glucagon-like Peptide-1 in Dermatology. PMC11932103. 2025. PubMed

Hair loss on GLP-1 therapy is typically temporary. It usually peaks 3–6 months after significant weight loss and resolves within 6–9 months as the body adapts. Adequate protein intake (≥1.2 g/kg body weight) and micronutrient sufficiency (iron, zinc, biotin) help mitigate this effect. For more detail, see our full guide on GLP-1 medications and hair loss.

GLP-1 Medications and Skin Aging: An Emerging Research Frontier

A 2024 paper in Ageing Research Reviews proposed a broader framework: GLP-1 receptor agonists may counter several hallmarks of skin aging through systemic mechanisms.

The proposed anti-aging pathways include:

Reduced AGE accumulation — GLP-1 therapy lowers blood glucose, reducing glycation of skin collagen
Lower systemic inflammation — chronic low-grade inflammation drives skin aging; GLP-1 suppresses it
Improved microvascular function — better blood flow enhances oxygen and nutrient delivery to skin
Stem cell protection — preliminary evidence suggests GLP-1 agonists may reduce oxidative stress in skin progenitor cells

Evidence: "Semaglutide may contribute to healthy skin aging by targeting key hallmarks of aging, including chronic inflammation, oxidative stress, and advanced glycation end-product accumulation." — Semaglutide as a possible therapy for healthy aging. Ageing Research Reviews. 2024. DOI: 10.1016/j.arr.2024.102582

This research is still early-stage. No large-scale RCT has evaluated GLP-1 therapy specifically for skin aging outcomes. However, the mechanistic overlap is scientifically plausible and warrants further investigation.

Key Takeaways

GLP-1 receptor agonists have direct anti-inflammatory effects via immune cell modulation, reducing cytokines that drive psoriasis and hidradenitis suppurativa.
Psoriasis responds measurably to semaglutide in obese patients — PASI scores dropped >50% in a 12-week RCT.
Hidradenitis suppurativa shows promising clinical improvement, with 54% of patients achieving disease control in a multicenter French study.
"Ozempic face" is a real phenomenon driven by rapid fat loss, not a direct drug toxicity. Slower weight loss and resistance training reduce its severity.
Hair loss is common but temporary — it reflects calorie restriction physiology, not a permanent drug effect.
Skin aging research is emerging, with plausible mechanisms linking GLP-1 therapy to reduced glycation and inflammation in skin.

Patients starting GLP-1 therapy should discuss skin expectations with their provider — both the potential therapeutic benefits for inflammatory skin conditions and the aesthetic changes that may accompany significant weight loss.

References

Haykal T, et al. The Role of GLP-1 Agonists in Esthetic Medicine: Exploring the Impact of Semaglutide on Body Contouring and Skin Health. Journal of Cosmetic Dermatology. 2025. DOI: 10.1111/jocd.16716
Effects of Semaglutide Treatment on Psoriatic Lesions in Obese Patients with Type 2 Diabetes Mellitus: An Open-Label, Randomized Clinical Trial. Biomolecules. 2025;15(1):46. DOI: 10.3390/biom15010046
Gouvrion L, Delage M, Villani AP, et al. Glucagon-like Peptide-1 Receptor Agonists in Hidradenitis Suppurativa. JAMA Dermatology. 2025. DOI: 10.1001/jamadermatol.2025.2723
Montecinos A, et al. Semaglutide "Ozempic" Face and Implications in Cosmetic Dermatology. Dermatological Reviews. 2024. DOI: 10.1002/der2.70003
A Review of Glucagon-like Peptide-1 in Dermatology. PMC. 2025. PubMed
Semaglutide as a possible therapy for healthy aging: Targeting the hallmarks of aging. Ageing Research Reviews. 2024. DOI: 10.1016/j.arr.2024.102582
Impact of glucagon-like peptide-1 receptor agonists on cutaneous events: A systematic review and meta-analysis. JAAD Reviews. 2025. DOI: 10.1016/j.jadr.2025.00054

Last updated: 2026-04-14 Medical review: Dr. James Chen, MD, PhD, FACE